Drugs / NK cell therapy
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05108012 | Aug → Nov 2021 | glioblastoma | Royan Institute | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06687681 | Nov 2024 → Nov 2025 overdue | glioblastoma | Marzieh Ebrahimi | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK cell therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05108012 ↗ |
| Action | Deplete | “can effectively identify and eliminate cancer cells” NCT06687681 ↗ |
| Modality | Cell therapy | “cell therapy with NK cells” NCT05108012 ↗ |
| Route | Other | “NK cell injection in tumor cavity.” NCT05108012 ↗ |